Literature DB >> 263348

Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.

R J Santen, S Santner, B Davis, J Veldhuis, E Samojlik, E Ruby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 263348     DOI： 10.1210/jcem-47-6-1257

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  52 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.

Authors:  P E Lønning; M Dowsett; A Jones; D Ekse; S Jacobs; F McNeil; D C Johannessen; T J Powles
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 3.  Solving the puzzle of hormone-dependent breast cancer.

Authors:  R J Santen
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 4.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 5.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

6.  Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

Authors:  Monica Milani; Gautam Jha; David A Potter
Journal:  Clin Med Ther       Date:  2009-03-31

7.  Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.

Authors:  E M Quinn; C Fleming; M J O'Sullivan
Journal:  Ir J Med Sci       Date:  2015-05-14       Impact factor: 1.568

Review 8.  Key issues in the treatment of advanced breast cancer. Expectations and outcomes.

Authors:  R D Rubens
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 9.  Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.

Authors:  R J Santen
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.

Authors:  S Kvinnsland; O Dahl
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.